Key Takeaways
- • Alantra Private Equity has completed two additional dental laboratory acquisitions through its AIVORIQ platform, expanding the group to over 20 laboratories across Spain with approximately €40 million in annual revenues.
- • AIVORIQ now operates as one of Spain's leading consolidated dental laboratory groups, with capabilities spanning fixed prosthetics, aesthetic treatments, and orthodontics, serving primarily independent dental clinics.
- • The platform has achieved significant growth through a dual strategy combining strong double-digit organic expansion with disciplined buy-and-build execution in a highly fragmented market characterized by thousands of independent operators.
- • Acquired laboratory owners are reinvesting in AIVORIQ and retaining operational involvement, aligning founder incentives with platform growth and ensuring continuity of entrepreneurial expertise—a model identified as critical to the group's integration success.
- • AIVORIQ targets expansion to approximately 30 laboratories in Spain, with long-term European market entry objectives, positioning the platform to capture consolidation upside in a fragmented €2+ billion Spanish dental laboratory sector.
Summary
Alantra Private Equity has strengthened its dental laboratory consolidation platform, AIVORIQ, through two recent acquisitions that reinforce the group's position as one of Spain's leading dental laboratory operators. The newly acquired laboratories expand AIVORIQ's nationwide footprint and enhance its service capabilities in fixed prosthetics, aesthetic treatments, and orthodontics. These facilities principally serve independent dental clinics and bring advanced digital design capabilities that improve precision, reduce turnaround times, and enhance overall service quality.
Since Alantra PE established AIVORIQ, the platform has grown substantially to comprise more than 20 dental laboratories across Spain, generating approximately €40 million in annual revenues. This expansion reflects the execution of a capital-efficient buy-and-build strategy in a market characterized by significant fragmentation, with thousands of independent operators presenting substantial consolidation opportunity. The group has achieved this scale through a combination of strong double-digit organic growth and disciplined M&A execution.
A distinguishing feature of AIVORIQ's integration model is founder reinvestment and continued operational involvement. Owners of acquired laboratories are reinvesting equity into the platform and remaining engaged in management, creating alignment between former founders and the group's next growth phase. This approach has proven instrumental to AIVORIQ's success, preserving entrepreneurial expertise and operational continuity while building a scalable, technology-enabled platform capable of delivering high-quality services across a distributed network.
The Spanish dental laboratory sector remains highly fragmented, with limited large-scale operators and significant scope for market consolidation. AIVORIQ's strategy focuses on building an integrated platform that combines operational scale with technological capability while maintaining the specialized expertise of acquired laboratories. The platform expects to continue expansion with a target of approximately 30 laboratories in Spain, with longer-term objectives to enter additional European markets, positioning the group to capture further consolidation upside in this underconsolidated sector.
Since Alantra PE established AIVORIQ, the platform has grown substantially to comprise more than 20 dental laboratories across Spain, generating approximately €40 million in annual revenues. This expansion reflects the execution of a capital-efficient buy-and-build strategy in a market characterized by significant fragmentation, with thousands of independent operators presenting substantial consolidation opportunity. The group has achieved this scale through a combination of strong double-digit organic growth and disciplined M&A execution.
A distinguishing feature of AIVORIQ's integration model is founder reinvestment and continued operational involvement. Owners of acquired laboratories are reinvesting equity into the platform and remaining engaged in management, creating alignment between former founders and the group's next growth phase. This approach has proven instrumental to AIVORIQ's success, preserving entrepreneurial expertise and operational continuity while building a scalable, technology-enabled platform capable of delivering high-quality services across a distributed network.
The Spanish dental laboratory sector remains highly fragmented, with limited large-scale operators and significant scope for market consolidation. AIVORIQ's strategy focuses on building an integrated platform that combines operational scale with technological capability while maintaining the specialized expertise of acquired laboratories. The platform expects to continue expansion with a target of approximately 30 laboratories in Spain, with longer-term objectives to enter additional European markets, positioning the group to capture further consolidation upside in this underconsolidated sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.